OptiNose

OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal Bi-Directional Delivery which allows drugs to be more efficiently delivered to the nasal cavity. By applying the Company's drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices.

The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, the technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown the devices can provide a faster onset of action, greater effect with a lower dose and reduced side effects.

Company Growth (employees)
Type
Public
HQ
Oslo, NO
Founded
2000
Size (employees)
44 (est)+5%
OptiNose was founded in 2000 and is headquartered in Oslo, NO

Key People/Management at OptiNose

Peter Miller

Peter Miller

CEO
Ramy Mahmoud

Ramy Mahmoud

President
Per Djupesland

Per Djupesland

CSO

OptiNose Office Locations

OptiNose has offices in Oslo and Berkeley
Oslo, NO (HQ)
Oslo Innovation Center
Berkeley, US
Berkeley House
Show all (2)

OptiNose Financials and Metrics

OptiNose Financials

OptiNose's revenue was reported to be $47.5 m in FY, 2016
USD

Net income (Q3, 2017)

(13.1 m)

EBIT (Q3, 2017)

(13.2 m)

Market capitalization (31-Oct-2017)

761.3 m

Closing share price (31-Oct-2017)

20

Cash (30-Sep-2017)

49.4 m
OptiNose's current market capitalization is $761.3 m.
USDFY, 2015FY, 2016

Revenue

85 k47.5 m

Revenue growth, %

55782%

R&D expense

22.2 m15.3 m

General and administrative expense

6 m6.9 m
USDQ3, 2016Q3, 2017

R&D expense

3.9 m6.6 m

General and administrative expense

1.8 m6.6 m

Operating expense total

5.6 m13.2 m

EBIT

(5.6 m)(13.2 m)
USDFY, 2015FY, 2016

Cash

15.2 m36.8 m

Accounts Receivable

448 k384 k

Current Assets

15.8 m40.7 m

PP&E

191 k323 k
USDQ3, 2017

Cash

49.4 m

Accounts Receivable

231 k

Current Assets

50.3 m

PP&E

1.4 m
USDFY, 2015FY, 2016

Net Income

(28.3 m)22.6 m

Accounts Receivable

144 k65 k

Accounts Payable

450 k(130 k)

Cash From Operating Activities

(28.7 m)21.7 m
USDQ3, 2016Q3, 2017

Net Income

28.2 m(29.4 m)

Accounts Receivable

(333 k)159 k

Inventories

(241 k)

Accounts Payable

(524 k)(574 k)
Y, 2017

Financial Leverage

-0.3 x
Show all financial metrics

OptiNose Operating Metrics

Jun, 2017

Patents (US)

43

Patents Pending (US)

35

Trademarks (US)

3
Show all operating metrics

OptiNose Market Value History

OptiNose's Web-traffic and Trends

OptiNose Company Life and Culture

You may also be interested in